Roberto Massimo Lemoli

List of Publications by Year
in descending order

173 papers	10,589 citations	41344 49 h-index	34986 98 g-index

173 all docs	173 docs citations	173 times ranked	13240 citing authors

#	Article	IF	Citations
1	Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. New England Journal of Medicine, 2020, 383, 617-629.	27.0	1,407
2	The P2X7 Receptor: A Key Player in IL-1 Processing and Release. Journal of Immunology, 2006, 176, 3877-3883.	0.8	949
3	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet, The, 2019, 394, 2096-2107.	13.7	435
4	Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematology,the, 2020, 7, e737-e745.	4.6	430
5	Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood, 2002, 100, 230-237.	1.4	393
6	Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25â˜' into CD25+ T regulatory cells. Blood, 2007, 109, 2871-2877.	1.4	357
7	Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood, 2011, 118, 3273-3279.	1.4	356
8	The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology. Blood, 2009, 113, 2394-2401.	1.4	237
9	Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++IL-12low/neg accessory cells with dendritic-cell features. Blood, 2006, 108, 218-227.	1.4	226
10	Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells. Blood, 1996, 87, 1625-1634.	1.4	162
11	Proposed definition of â€˜poor mobilizerâ€™ in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo. Bone Marrow Transplantation, 2012, 47, 342-351.	2.4	156
12	Molecular Remission After Allogeneic or Autologous Transplantation of Hematopoietic Stem Cells for Multiple Myeloma. Journal of Clinical Oncology, 2000, 18, 2273-2281.	1.6	153
13	Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation. Bone Marrow Transplantation, 2014, 49, 865-872.	2.4	151
14	Regulatory T cells and tolerogenic dendritic cells: from basic biology to clinical applications. Immunology Letters, 2004, 94, 11-26.	2.5	134
15	Nucleofection Is an Efficient Nonviral Transfection Technique for Human Bone Marrow-Derived Mesenchymal Stem Cells. Stem Cells, 2006, 24, 454-461.	3.2	123
16	Extracellular ATP Exerts Opposite Effects on Activated and Regulatory CD4+ T Cells via Purinergic P2 Receptor Activation. Journal of Immunology, 2012, 189, 1303-1310.	0.8	121
17	Granulocyte colonyâ€stimulating factor promotes the generation of regulatory DC through induction of ILâ€10 and IFNâ€γ. European Journal of Immunology, 2004, 34, 1291-1302.	2.9	120
18	Extracellular nucleotides are potent stimulators of human hematopoietic stem cells in vitro and in vivo. Blood, 2004, 104, 1662-1670.	1.4	111

#	Article	IF	Citations
19	Larger Size of Donor Alloreactive NK Cell Repertoire Correlates with Better Response to NK Cell Immunotherapy in Elderly Acute Myeloid Leukemia Patients. Clinical Cancer Research, 2016, 22, 1914-1921.	7.0	110
20	Cycling Status of CD34+ Cells Mobilized Into Peripheral Blood of Healthy Donors by Recombinant Human Granulocyte Colony-Stimulating Factor. Blood, 1997, 89, 1189-1196.	1.4	106
21	Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. Cancer, 2020, 126, 1243-1252.	4.1	106
22	A novel model of CCl4-induced cirrhosis with ascites in the mouse. Journal of Hepatology, 2009, 51, 991-999.	3.7	100
23	Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase. Leukemia, 2007, 21, 353-355.	7.2	99
24	Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells. Haematologica, 2010, 95, 2022-2030.	3.5	95
25	Extracellular Purines Promote the Differentiation of Human Bone Marrow-Derived Mesenchymal Stem Cells to the Osteogenic and Adipogenic Lineages. Stem Cells and Development, 2013, 22, 1097-1111.	2.1	95
26	The extracellular nucleotide UTP is a potent inducer of hematopoietic stem cell migration. Blood, 2007, 109, 533-542.	1.4	93
27	Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells. Blood, 2016, 127, 1138-1150.	1.4	89
28	Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes. Experimental Hematology, 2006, 34, 879-887.	0.4	88
29	Interleukin-11 induces Th2 polarization of human CD4+ T cells. Blood, 2001, 97, 2758-2763.	1.4	85
30	The sixth sense: hematopoietic stem cells detect danger through purinergic signaling. Blood, 2012, 120, 2365-2375.	1.4	83
31	The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. Bone Marrow Transplantation, 2011, 46, 356-363.	2.4	81
32	Mobilization of Bone Marrow-Derived Hematopoietic and Endothelial Stem Cells After Orthotopic Liver Transplantation and Liver Resection. Stem Cells, 2006, 24, 2817-2825.	3.2	79
33	Alloantigen presenting capacity, T cell alloreactivity and NK function of G-CSF-mobilized peripheral blood cells. Bone Marrow Transplantation, 1998, 22, 631-637.	2.4	76
34	Purinergic stimulation of human mesenchymal stem cells potentiates their chemotactic response to CXCL12 and increases the homing capacity and production of proinflammatory cytokines. Experimental Hematology, 2011, 39, 360-374.e5.	0.4	73
35	The SOCS3-Independent Expression of IDO2 Supports the Homeostatic Generation of T Regulatory Cells by Human Dendritic Cells. Journal of Immunology, 2014, 192, 1231-1240.	0.8	72
36	Impact of Venetoclax and Azacitidine in Treatment-NaÃ¯ve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations. Clinical Cancer Research, 2022, 28, 2753-2761.	7.0	70

#	Article	IF	Citations
37	Harnessing NK Cells for Cancer Treatment. Frontiers in Immunology, 2019, 10, 2836.	4.8	66
38	In vitroanti-tumour activity of anti-CD80 and anti-CD86 immunotoxins containing type 1 ribosome-inactivating proteins. British Journal of Haematology, 2000, 110, 351-361.	2.5	65
39	Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis. Oncotarget, 2017, 8, 79073-79086.	1.8	63
40	Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34â^' cell population with intrinsic resistance to imatinib. Blood, 2009, 114, 5191-5200.	1.4	62
41	Stem Cell Factor and FLT3-Ligand Are Strictly Required to Sustain the Long-Term Expansion of Primitive CD34+DRâ^'Dendritic Cell Precursors. Journal of Immunology, 2001, 166, 848-854.	0.8	61
42	Generation and functional characterization of human dendritic cells derived from CD34+cells mobilized into peripheral blood: comparison with bone marrow CD34+cells. British Journal of Haematology, 1998, 101, 756-765.	2.5	60
43	Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patientâ€specific tumour idiotype protein or idiotype (VDJ)â€derived class Iâ€restricted peptides. British Journal of Haematology, 2007, 139, 415-424.	2.5	58
44	Preemptive use of plerixafor in difficultâ€toâ€mobilize patients: an emerging concept. Transfusion, 2012, 52, 906-914.	1.6	56
45	COVIDâ€19 elicits an impaired antibody response against SARSâ€CoVâ€2 in patients with haematological malignancies. British Journal of Haematology, 2021, 195, 371-377.	2.5	56
46	Fludarabine-containing regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid leukaemia patients. British Journal of Haematology, 1999, 105, 775-779.	2.5	55
47	High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma. Bone Marrow Transplantation, 1998, 22, 27-32.	2.4	54
48	European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization. Bone Marrow Transplantation, 2012, 47, 1046-1050.	2.4	54
49	PGE₂-Induced IDO1 Inhibits the Capacity of Fully Mature DCs to Elicit anIn VitroAntileukemic Immune Response. Journal of Immunology Research, 2015, 2015, 1-10.	2.2	53
50	Stem cell mobilization and collection in patients with liver cirrhosis. Alimentary Pharmacology and Therapeutics, 2008, 27, 932-939.	3.7	52
51	Purinergic signaling inhibits human acute myeloblastic leukemia cell proliferation, migration, and engraftment in immunodeficient mice. Blood, 2012, 119, 217-226.	1.4	52
52	Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells. Oncotarget, 2017, 8, 49451-49469.	1.8	49
53	Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cellsâ€™ vulnerability to DNA-damaging agents. Haematologica, 2018, 103, 80-90.	3.5	48
54	Efficient presentation of tumor idiotype to autologous T cells by CD83+ dendritic cells derived from highly purified circulating CD14+ monocytes in multiple myeloma patients. Experimental Hematology, 2000, 28, 931-940.	0.4	46

#	Article	IF	Citations
55	The tissue inhibitor of metalloproteinases-1 (TIMP-1) promotes survival and migration of acute myeloid leukemia cells through CD63/PI3K/Akt/p21 signaling. Oncotarget, 2017, 8, 2261-2274.	1.8	46
56	Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients. Hematological Oncology, 2018, 36, 561-569.	1.7	46
57	The Kinetic Status of Hematopoietic Stem Cell Subpopulations Underlies a Differential Expression of Genes Involved in Self-Renewal, Commitment, and Engraftment. Stem Cells, 2005, 23, 496-506.	3.2	45
58	Extracellular ATP induces apoptosis through P2X7R activation in acute myeloid leukemia cells but not in normal hematopoietic stem cells. Oncotarget, 2017, 8, 5895-5908.	1.8	45
59	Interleukin-12 production by leukemia-derived dendritic cells counteracts the inhibitory effect of leukemic microenvironment on T cells. Experimental Hematology, 2005, 33, 1521-1530.	0.4	44
60	Generation of dendritic cells from CD14+ monocytes positively selected by immunomagnetic adsorption for multiple myeloma patients enrolled in a clinical trial of anti-idiotype vaccination. British Journal of Haematology, 2003, 121, 240-250.	2.5	43
61	Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia. Annals of Hematology, 2013, 92, 67-78.	1.8	43
62	Plerixafor for Autologous Peripheral Blood Stem Cell Mobilization in Patients Previously Treated with Fludarabine or Lenalidomide. Biology of Blood and Marrow Transplantation, 2012, 18, 314-317.	2.0	42
63	Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis. Blood Cancer Journal, 2021, 11, 4.	6.2	41
64	Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival compared with bone marrow cells. Bone Marrow Transplantation, 1999, 24, 467-472.	2.4	40
65	Generation of Dendritic Cells from Positively Selected CD14â€Š+â€ŠMonocytes for Anti-tumor Immunotherapy. Leukemia and Lymphoma, 2004, 45, 1419-1428.	1.3	40
66	Factors affecting successful mobilization with plerixafor: an <scp>I</scp>talian prospective survey in 215 patients with multiple myeloma and lymphoma. Transfusion, 2014, 54, 331-339.	1.6	39
67	Hematopoietic stem cell mobilization. Haematologica, 2008, 93, 321-324.	3.5	38
68	Evaluation of immunotoxins containing single-chain ribosome-inactivating proteins and an anti-CD22 monoclonal antibody (OM124): in vitro and in vivo studies. British Journal of Haematology, 1998, 101, 179-188.	2.5	35
69	Immunotoxins Containing Recombinant Anti-CTLA-4 Single-Chain Fragment Variable Antibodies and Saporin: In Vitro Results and In Vivo Effects in an Acute Rejection Model. Journal of Immunology, 2001, 167, 4222-4229.	0.8	34
70	Autologous transplantation of granulocyte colony-stimulating factorâ€“primed bone marrow is effective in supporting myeloablative chemotherapy in patients with hematologic malignancies and poor peripheral blood stem cell mobilization. Blood, 2003, 102, 1595-1600.	1.4	33
71	INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia. Blood Advances, 2022, 6, 1742-1753.	5.2	33
72	Interleukin-9 stimulates the proliferation of human myeloid leukemic cells. Blood, 1996, 87, 3852-3859.	1.4	31

#	Article	IF	Citations
73	Longâ€term followâ€up of patients with acute myeloid leukemia surviving and free of disease recurrence for at least 2 years after autologous stem cell transplantation: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer, 2016, 122, 1880-1887.	4.1	31
74	Rapid Induction of CD40 on a Subset of Granulocyte Colony-Stimulating Factorâ€“Mobilized CD34+ Blood Cells Identifies Myeloid Committed Progenitors and Permits Selection of Nonimmunogenic CD40â¯ Progenitor Cells. Blood, 1999, 94, 2293-2300.	1.4	30
75	Cancer Immunotherapy by Blocking Immune Checkpoints on Innate Lymphocytes. Cancers, 2020, 12, 3504.	3.7	30
76	Very Low Rate of Readmission after an Early Discharge Outpatient Model for Autografting in Multiple Myeloma Patients: An Italian Multicenter Retrospective Study. Biology of Blood and Marrow Transplantation, 2014, 20, 1026-1032.	2.0	28
77	CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program. Blood Cancer Journal, 2020, 10, 96.	6.2	28
78	Circulating CD4+CD161+CD196+ Th17 cells are not increased in immune thrombocytopenia. Haematologica, 2011, 96, 632-634.	3.5	27
79	Reduced susceptibility to apoptosis correlates with kinetic quiescence in disease progression of chronic lymphocytic leukaemia. British Journal of Haematology, 2001, 113, 391-399.	2.5	26
80	Human cord blood-derived platelet lysate enhances the therapeutic activity of adipose-derived mesenchymal stromal cells isolated from Crohnâ€™s disease patients in a mouse model of colitis. Stem Cell Research and Therapy, 2015, 6, 170.	5.5	26
81	Italian consensus conference for the outpatient autologous stem cell transplantation management in multiple myeloma. Bone Marrow Transplantation, 2016, 51, 1032-1040.	2.4	26
82	Combining flow cytometry and WT1 assessment improves the prognostic value of pre-transplant minimal residual disease in acute myeloid leukemia. Haematologica, 2017, 102, e348-e351.	3.5	26
83	Selection and transplantation of autologous CD34+ B-lineage negative cells in advanced-phase multiple myeloma patients: a pilot study. British Journal of Haematology, 1999, 107, 419-428.	2.5	25
84	Selection and Transplantation of Autologous Hematopoietic CD34+Cells for Patients with Multiple Myeloma. Leukemia and Lymphoma, 1997, 26, 1-11.	1.3	24
85	T cell alloreactivity induced by normal G-CSF-mobilized CD34+ blood cells. Bone Marrow Transplantation, 1998, 21, 1183-1191.	2.4	24
86	The tissue inhibitor of metalloproteinases 1 increases the clonogenic efficiency of human hematopoietic progenitor cells through CD63/PI3K/Akt signaling. Experimental Hematology, 2015, 43, 974-985.e1.	0.4	24
87	Autologous stem cell transplantation is still a valid option in good- and intermediate-risk AML: a GITMO survey on 809 patients autografted in first complete remission. Bone Marrow Transplantation, 2017, 52, 163-166.	2.4	24
88	Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter studyâŽ. Seminars in Hematology, 2018, 55, 248-255.	3.4	24
89	Positive Selection and Transplantation of Autologous Highly Purified CD133+ Stem Cells in Resistant/Relapsed Chronic Lymphocytic Leukemia Patients Results in Rapid Hematopoietic Reconstitution without an Adequate Leukemic Cell Purging. Biology of Blood and Marrow Transplantation, 2007, 13, 1224-1232.	2.0	23
90	Molecular profile of CD34+ stem/progenitor cells according to JAK2V617F mutation status in essential thrombocythemia. Leukemia, 2009, 23, 997-1000.	7.2	22

#	Article	IF	Citations
91	NEW STRATEGIES FOR STEM CELL MOBILIZATION. Mediterranean Journal of Hematology and Infectious Diseases, 2012, 4, e2012066.	1.3	22
92	Age and comorbidities deeply impact on clinical outcome of patients with myelodysplastic syndromes. Leukemia Research, 2015, 39, 846-852.	0.8	22
93	Reinfusion of highly purified CD133+ bone marrow-derived stem/progenitor cells in patients with end-stage liver disease: A phase I clinical trial. Digestive and Liver Disease, 2015, 47, 1059-1066.	0.9	22
94	Autologous peripheral blood stem cell transplantation in acute myeloblastic leukaemia and myelodysplastic syndrome patients: evaluation of tumour cell contamination of leukaphereses by cytogenetic and molecular methods. Bone Marrow Transplantation, 1998, 22, 1065-1070.	2.4	21
95	The CD47 pathway is deregulated in human immune thrombocytopenia. Experimental Hematology, 2011, 39, 486-494.	0.4	21
96	CD103 marks a subset of human CD34+-derived langerin+ dendritic cells that induce T-regulatory cells via indoleamine 2,3-dioxygenase-1. Experimental Hematology, 2015, 43, 268-276.e5.	0.4	21
97	Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USA. Bone Marrow Transplantation, 2012, 47, 18-23.	2.4	20
98	Concomitant and sequential administration of recombinant human granulocyte colony-stimulating factor and recombinant human interleukin-3 to accelerate hematopoietic recovery after autologous bone marrow transplantation for malignant lymphoma.. Journal of Clinical Oncology, 1996, 14, 3018-3025.	1.6	19
99	Gpr171, a putative P2Y-like receptor, negatively regulates myeloid differentiation in murine hematopoietic progenitors. Experimental Hematology, 2013, 41, 102-112.	0.4	19
100	Dual NAMPT and BTK Targeting Leads to Synergistic Killing of WaldenstrÃ¶m Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status. Clinical Cancer Research, 2016, 22, 6099-6109.	7.0	19
101	Amino acid depletion triggered by ÊŸ-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death. Blood Advances, 2020, 4, 4312-4326.	5.2	19
102	Second primary malignancy in myelofibrosis patients treated with ruxolitinib. British Journal of Haematology, 2021, 193, 356-368.	2.5	19
103	High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by riskâ€oriented consolidation: A critical review of a 10â€year, singleâ€center experience in younger, non M3 AML patients. American Journal of Hematology, 2016, 91, 755-762.	4.1	18
104	BU/melphalan and auto-SCT in AML patients in first CR: a â€˜Gruppo Italiano Trapianto di Midollo Osseo (GITMO)â€™ retrospective study. Bone Marrow Transplantation, 2010, 45, 640-646.	2.4	17
105	European data on stem cell mobilization with plerixafor in patients with nonhematologic diseases: an analysis of the European consortium of stem cell mobilization. Transfusion, 2012, 52, 2395-2400.	1.6	17
106	Haploidentical Transplants with Post-Transplant Cyclophosphamide for Relapsed or Refractory Hodgkin Lymphoma: The Role of Comorbidity Index and Pretransplant Positron Emission Tomography. Biology of Blood and Marrow Transplantation, 2018, 24, 2501-2508.	2.0	17
107	C-kit ligand (SCF) in human multiple myeloma cells. Leukemia and Lymphoma, 1996, 20, 457-464.	1.3	16
108	Thrombopoietin and interleukin 11 have different modulatory effects on cell cycle and programmed cell death in primary acute myeloid leukemia cells. Experimental Hematology, 1999, 27, 1255-1263.	0.4	16

#	Article	IF	Citations
109	Impaired Dendritic Cell Immunophenotype and Function in Heart Transplant Patients Undergoing Active Cytomegalovirus Infection. Transplantation, 2005, 79, 219-227.	1.0	16
110	A blastic plasmacytoid dendritic cell neoplasmâ€like phenotype identifies a subgroup of npm1â€mutated acute myeloid leukemia patients with worse prognosis. American Journal of Hematology, 2018, 93, E33-E35.	4.1	16
111	Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia. Annals of Hematology, 2014, 93, 2011-2018.	1.8	15
112	Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Realâ€world data. Hematological Oncology, 2020, 38, 372-380.	1.7	15
113	Effects of granulocyte colony stimulating-factor in a rat model of acute liver injury. Digestive and Liver Disease, 2007, 39, 943-951.	0.9	14
114	Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome. Cancer, 2021, 127, 2657-2665.	4.1	14
115	Mechanisms and Clinical Applications of Genome Instability in Multiple Myeloma. BioMed Research International, 2015, 2015, 1-8.	1.9	13
116	Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (<scp>FLAI</scp>) provides the most useful prognostic information. British Journal of Haematology, 2019, 184, 457-460.	2.5	13
117	Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study. Bone Marrow Transplantation, 1999, 23, 235-241.	2.4	12
118	Functional and kinetic characterization of granulocyte colony-stimulating factor-primed CD34â˜' human stem cells. British Journal of Haematology, 2003, 123, 720-729.	2.5	12
119	The new small tyrosine kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs. Haematologica, 2020, 105, 2420-2431.	3.5	12
120	Superiority of Double over Single Autologous Stem Cell Transplantation as First-Line Therapy for Multiple Myeloma.. Blood, 2004, 104, 536-536.	1.4	12
121	Peripheral Blood Mobilization of Hematopoietic Stem Cells: Cytokine-Mediated Regulation of Adhesive Interactions within the Hematopoietic Microenvironment. Acta Haematologica, 1997, 97, 90-96.	1.4	11
122	Higher BMI is not a barrier to stem cell mobilization with standard doses of plerixafor and G-CSF. Bone Marrow Transplantation, 2012, 47, 1003-1005.	2.4	11
123	Combined assessment of WT1 and BAALC gene expression at diagnosis may improve leukemia-free survival prediction in patients with myelodysplastic syndromes. Leukemia Research, 2015, 39, 866-873.	0.8	11
124	Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib. Annals of Hematology, 2019, 98, 889-896.	1.8	10
125	Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of FLT3-ITD in NPM1 Mutated AML, Irrespectively of FLT3-ITD Allelic Burden. Cancers, 2021, 13, 34.	3.7	10
126	Megakaryocyte progenitors derived from bone marrow or Gâ€CSFâ€mobilized peripheral blood CD34+cells show a distinct phenotype and responsiveness to interleukinâ€3 (ILâ€3) and PEGâ€recombinant human megakaryocyte growth and development factor (PEGâ€rHuMGDF). British Journal of Haematology, 1998, 100, 207-218.	2.5	9

#	Article	IF	Citations
127	Selective expansion of normal haemopoietic progenitors from chronic myelogenous leukaemia marrow. British Journal of Haematology, 1998, 101, 119-129.	2.5	9
128	Longitudinal minimal residual disease (MRD) evaluation in acute myeloid leukaemia with NPM1 mutation: from definition of molecular relapse to MRDâ€driven salvage approach. British Journal of Haematology, 2019, 186, e223-e225.	2.5	9
129	Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study. Cancer Medicine, 2021, 10, 1726-1737.	2.8	9
130	Impact of comorbidities and body mass index on the outcome of polycythemia vera patients. Hematological Oncology, 2021, 39, 409-418.	1.7	9
131	Interleukin-9 in Human Myeloid Leukemia Cells. Leukemia and Lymphoma, 1997, 26, 563-573.	1.3	8
132	Human responses against HER-2-positive cancer cells in human immune system-engrafted mice. British Journal of Cancer, 2012, 107, 1302-1309.	6.4	8
133	Characterization of autotransplant-related thrombocytopenia by evaluation of glycocalicin and reticulated platelets. Bone Marrow Transplantation, 1999, 24, 1191-1194.	2.4	7
134	Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patients. Bone Marrow Transplantation, 2001, 27, 829-835.	2.4	7
135	Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT) Tj ETQq1 1 0.784314 rgBT /Ove	1.3	7
136	Molecular and functional characterization of CD133 + stem/progenitor cells infused in patients with end-stage liver disease reveals their interplay with stromal liver cells. Cytotherapy, 2017, 19, 1447-1461.	0.7	7
137	Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients. British Journal of Haematology, 2018, 183, 35-46.	2.5	7
138	A simple cytofluorimetric score may optimize testing for biallelic CEBPA mutations in patients with acute myeloid leukemia. Leukemia Research, 2019, 86, 106223.	0.8	7
139	Dexamethasone, oxaliplatin and cytarabine (R-DHAOx) as salvage and stem cells mobilizing therapy in relapsed/refractory diffuse large B cell lymphomas. Leukemia and Lymphoma, 2020, 61, 84-90.	1.3	7
140	Preâ€transplant minimal residual disease assessment and transplantâ€related factors predict the outcome of acute myeloid leukemia patients undergoing allogeneic stem cell transplantation. European Journal of Haematology, 2021, 107, 573-582.	2.2	7
141	Transforming growth factor Î²3 inhibits chronic myelogenous leukemia hematopoiesis by inducing Fas-independent apoptosis. Experimental Hematology, 2000, 28, 775-783.	0.4	6
142	Dendritic Cell Differentiation. Journal of Immunology, 2004, 172, 3-4.	0.8	6
143	The Human Mesenchymal Stromal Cell-Derived Osteocyte Capacity to Modulate Dendritic Cell Functions Is Strictly Dependent on the Culture System. Journal of Immunology Research, 2015, 2015, 1-10.	2.2	6
144	Autologous stem cell transplantation for acute myeloid leukemia patients in first complete remission: a 10-year follow-up study of 118 patients. Haematologica, 2005, 90, 139-41.	3.5	6

#	Article	IF	Citations
145	High-Dose Therapy with Autologous Transplantation for Aggressive Non-Hodgkin's Lymphoma: The Bologna Experience. Leukemia and Lymphoma, 2004, 45, 321-326.	1.3	5
146	Novel strategies of adoptive immunotherapy: How natural killer cells may change the treatment of elderly patients with acute myeloblastic leukemia. Experimental Hematology, 2017, 45, 10-16.	0.4	5
147	Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity scoreâ€matched analysis. Cancer Medicine, 2019, 8, 7567-7576.	2.8	5
148	Intesive fludarabine-high dose cytarabine-idarubicin combination as induction therapy with risk-adapted consolidation may improve treatment efficacy in younger Acute Myeloid Leukemia (AML) patients: Rationales, evidences and future perspectives. BioScience Trends, 2017, 11, 110-114.	3.4	4
149	Regulatory T cells from patients with end-stage organ disease can be isolated, expanded and cryopreserved according good manufacturing practice improving their function. Journal of Translational Medicine, 2019, 17, 250.	4.4	4
150	Prognostic relevance of a blastic plasmacytoid dendritic cell neoplasm-like immunophenotype in cytogenetically normal acute myeloid leukemia patients. Leukemia and Lymphoma, 2020, 61, 1695-1701.	1.3	4
151	Conditioning regimen using busulfan plus melphalan in hematopoietic stem cell transplantation. Revista Brasileira De Hematologia E Hemoterapia, 2011, 33, 172-173.	0.7	4
152	Process development and validation of expanded regulatory T cells for prospective applications: an example of manufacturing a personalized advanced therapy medicinal product. Journal of Translational Medicine, 2022, 20, 14.	4.4	4
153	Combined Use of Growth Factors to Stimulate the Proliferation of Hematopoietic Progenitor Cells after Autologous Bone Marrow Transplantation for Lymphoma Patients. Acta Haematologica, 1996, 95, 164-170.	1.4	3
154	Negative selection of autologous peripheral blood stem cells. Best Practice and Research in Clinical Haematology, 1999, 12, 57-69.	1.7	3
155	Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. Hematological Oncology, 2019, 37, 418-423.	1.7	3
156	The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma. Bone Marrow Transplantation, 2020, 55, 946-954.	2.4	3
157	Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients. Oncotarget, 2018, 9, 21758-21769.	1.8	3
158	Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells. Frontiers in Immunology, 2021, 12, 753890.	4.8	3
159	Thrombopoietin, Interleukin-11, and Early-Acting Megakaryocyte Growth Factors in Human Myeloid Leukemia Cells. Leukemia and Lymphoma, 2000, 40, 179-190.	1.3	2
160	Quantitative Evaluation of BCR-ABL Amount of Transcript Post Mobilization with G-CSF of Peripheral Blood Stem Cells from Chronic Myeloid Leukemia Patients in Cytogenetic Response. Leukemia and Lymphoma, 2000, 39, 113-120.	1.3	2
161	Feasibility of Single-Port Laparoscopic Lymph Node Biopsy for Intra-Abdominal Lymphoma: A Case Series. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2021, 31, 458-461.	1.0	2
162	Feasibility and Efficacy of Post-Transplant Consolidation Immunotherapy with Nivolumab Supported By the Reinfusion of Unselected Autologous Lymphocytes in Patients Affected By Relapsed/Refractory Hodgkin Lymphoma. Blood, 2018, 132, 4598-4598.	1.4	2

#	Article	IF	Citations
163	Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy. Blood, 2000, 95, 2234-2239.	1.4	2
164	OUP accepted manuscript. Journal of Surgical Case Reports, 2022, 2022, rjac047.	0.4	2
165	Intensive Fludarabine, High Dose Cytarabine and Idarubicin-Based Induction for Younger NPM1-Mutated AML Patient: Overcoming the Negative Prognosis of FLT3-ITD Mutation. Blood, 2020, 136, 32-33.	1.4	1
166	A Novel Synthetic Lethal Approach Targeting SIRT6 in Acute Myeloid Leukemia. Blood, 2015, 126, 1375-1375.	1.4	1
167	Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma. Blood, 2000, 96, 355-357.	1.4	1
168	Therapy-Related AML (t-AML), a Heterogeneous Disease: Multicenter Analysis on Biological and Clinical Differences between Cases Following Breast Cancer and Lymphoma Treatment. Blood, 2020, 136, 31-31.	1.4	1
169	More ADO about IDO: GVHD. Blood, 2008, 111, 2950-2950.	1.4	0
170	Exploiting tumor vulnerabilities: NAD⁺-depleting agents combined with anti-tumor drugs as innovative strategy to treat hematological malignancies. Expert Review of Anticancer Therapy, 2016, 16, 897-898.	2.4	0
171	Prompt detection of Lâ€asparaginase inactivation is crucial to optimize treatment efficacy also in aggressive lymphomas. Hematological Oncology, 2018, 36, 498-499.	1.7	0
172	The Immunoregulatory Enzyme Indoleamine 2,3-Dioxygenase (IDO1) Is Expressed by Natural Killer (NK) Cells During Cytokine-Mediated Activation. Blood, 2010, 116, 3894-3894.	1.4	0
173	First Line Treatment with Hydroxyurea in Patients with Policitemia Vera: Evaluation of Efficacy in the Current Clinical Practice Beyond ELN Criteria. Blood, 2020, 136, 43-44.	1.4	0